Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Decisions in HIV Care: Managing ART With Opportunistic Infections

In this on-demand recording of a live webinar, expert faculty review key considerations for the use of ART in the setting of opportunistic infections. Topics include current data and recommendations for patients with pneumocystis pneumonia, Kaposi sarcoma, cytomegalovirus, and cryptococcal meningitis.
Cristina Mussini, MD
William R. Short, MD, MPH, AAHIVS
Released: April 5, 2022

In this episode from the series “Key Decisions in HIV Care,” Cristina Mussini, MD, and William R. Short, MD, MPH, AAHIVS, discuss important considerations for ART with opportunistic infections, including:

  • When to start ART with pneumocystis pneumonia including discussion of the ACTG 5164 study of immediate vs delayed ART with opportunistic infections
  • EACS, DHHS, and IAS-USA guideline recommendations for starting ART in the setting of most opportunistic infections
  • Considerations for the administration of ART to patients who are unable to swallow or critically ill and intubated
  • Treatment of Kaposi sarcoma and considerations for starting ART to avoid drug–drug interactions with Kaposi sarcoma treatment
  • Considerations for starting ART with cytomegalovirus and the risk for IRIS from cytomegalovirus
  • Discussion of treatment of cytomegalovirus and overlapping toxicities between its treatment and ART
  • When to start ART with cryptococcal meningitis and the data to support delayed treatment initiation with this particular opportunistic infection
  • EACS, DHHS, and IAS-USA guideline recommendations for starting ART in the setting of cryptococcal meningitis specifically
  • Treatment of cryptococcal meningitis and managing drug–drug interactions between ART and antifungal therapy

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Information on this Educational Activity

Faculty

Cristina Mussini, MD

Head of Department of Infectious Diseases and Tropical Medicine
Full Professor of Infectious Diseases

Infectious Diseases Clinics, University Hospital
University of Modena and Reggio Emilia
Modena, Italy

Cristina Mussini, MD, has disclosed that she has received consulting fees from AbbVie, Angelini, Gilead Sciences, Janssen, MSD, and ViiV Healthcare and funds for research support from Gilead Sciences, Janssen, MSD, and ViiV Healthcare.
William R. Short, MD, MPH, AAHIVS

Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

William R. Short, MD, MPH, AAHIVS, has disclosed that he has received fees for non-CME/CE services from Janssen and consulting fees from ViiV.

Program Medium

This program has been made available online.

Related Content

Dr Melissa Badowski shares key data about the causes of and recommendations for managing ART failure, from Clinical Care Options (CCO)

Melissa Badowski, PharmD, MPH, FIDSA, FCCP, BCIDP, BCPS, AAHIVP Physicians: maximum of 0.5 AMA PRA Category 1 Credits Pharmacists: 0.5 contact hours (0.05 CEUs) Released: December 23, 2022 Expired: December 22, 2023

Expert HIV faculty analyze new data from AIDS 2022, from Clinical Care Options (CCO)

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, AGPCNP-BC, ACRN, FAANP, FAAN, AAHIVS
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
Princy N. Kumar, MD, FIDSA, MACP person default Mary W. Montgomery, MD David A. Wohl, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Registered Nurses: 1.5 Nursing contact hours Pharmacists: 1.5 contact hours (0.15 CEUs) Released: December 23, 2022 Expired: December 22, 2023

Discussion of key considerations for monkeypox treatment, prevention, and care in people with HIV, from Clinical Care Options (CCO)

Monica Gandhi, MD, MPH Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Released: December 19, 2022

Discussion of monkeypox treatment and care options for people with HIV, from Clinical Care Options (CCO)

Monica Gandhi, MD, MPH Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Released: December 15, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings